Member Info for daveycaferacer

Yes they can, put yourself down as an "Individual Investor" and complete all the Fields. For website and LinkedIn profile make something up if you don't have them, it will still work.

We are not in any Index at the moment. until the next Index review which is in late March. At that point we should be included in the FTSE All Share Index but not until the review has taken place.

I think you have summed up the current situation very well LongOdds, and also JatW.

I am not hlding out too much hope that the approval of Savolitinib in China will give the Co's valuation a major boost given the fact it is only for Exon14-del, which has a very small target patient population. With the continual drive by the NPMA to reduce costs of drugs, whilst royalties are much higher in China the RoW it is the latter market that will provide the major financial benefit.

I am hopeful that Surufatinib's approval in the U.S and the EU will provide the biggest financial benefit over the medium to long term.

The Company has stated it aspires to become a fully integrated global pharma with a $20bn mcap as the next step in its evolution. I believe that will be achieved quite quickly if the pipeline continues to deliver but Iam frustrated that the current valuation is now at the same level as it was 3.5 years ago. Posters on here know I am a huge fan of the Company and its brilliant management team but also that I've looked at Beigene from the start of its NASDAQ listing and watched it soar as it does various deals.

I hope an Asian listing occurs soon as I believe the appetite for investing in the Company will be significant. Other Biotechs that have listed on the Star market or in HK have been extremely successful and I remain confident an Asian listing will help to drive better returns for long term Shareholders, returns that NASDAQ and London cannot seem to deliver.

I've emailed to suggest they remove all the AIM Rule 26 content from their website! They also have some obligations with a Main Listing for their website they haven't adhered to... ;o-/

people seem to think if they do not appear in their accounts, even with zero current value, they won't get them. If you are entitled to them you WILL receive them when they are listed. When will that be? No one knows yet!

Like many Brokers, AJ Bell have said they will credit accounts when they become trade-able, so when they are listed.

maybe, but there are some very small companies on the Main Market

it's a great video, looks as if Shailu is off to a funeral, it also appears his house may be on fire

stunning volume

Volume 19,463,902
Avg. Volume 522,485

correction

Volume 6,977,889
Avg. Volume 522,485

I have never seen this type of volume on NASDAQ before, this could easily hit well over 10 million +ADR's traded today, either trading will be halted or this could go much much higher yet

Volume 6,977,889
Avg. Volume 522,485

I have never seen this type of volume on NASDAQ before, this could easily hit well over 1 billion ADR's traded today, either trading will be halted or this could go much much higher yet

apologies, I was referring to the Covid trial news

I beg to disagree slightly on the subject of covid news. All we've had so far is anecdotal evidence and comments. If the actual data in terms of safety and efficacy is very good, that could make a material difference to the Company's prospects and valuation. It may not, but it certainly could.

In the short term there may be no effect. Looking at previous Companies some see a positive impact and some do not. I'd expect it to be included in the FTSE All Share Index at the next review in March. To be clear, it will not automatically be included in the Index tomorrow morning - it will only be included at the next review. Some Funds may begin to acquire holdings in anticipation of inclusion in the index but none are compelled to.

As tomorrow's fireside chat is at the Riley Oncology Conference I would expect the focus to be solely on Milciclib

well it's the last day on AIM tomorrow, let's hope the Main Market is a better place to be although just a word of caution, it doesn't guarantee success in any way but does tend to attract a different type of Investor

There is a very large spread at the moment, more manipulation probably

The similarity is the people only though, Tiziana has a much bigger, deeper late stage pipeline

https://www.okyopharma.com/about-us

You'll see the commonalities

They have one drug in pre-clinical, and one not even in the clinic, a very very early stage Company

"And if Tiziana doesn’t announce the Covid Brazil data today, their leadership is just as stupid as Steptoe is about the markets"

Before we get into the Americans v Brits, I will sit on the fence as I spend a lot of time in the United States and own a house there so I am a hybrid!

I disagree. They'd be a bit silly to announce the Brazil data today as the U.S. markets are closed so whilst they could, I doubt they will.